enzalutamid sandoz 80 mg filmom obalené tablety
sandoz pharmaceuticals d.d., slovinsko - enzalutamid - 44 - cytostatica
enzalutamid sandoz 40 mg filmom obalené tablety
sandoz pharmaceuticals d.d., slovinsko - enzalutamid - 44 - cytostatica
reseligo 10,8 mg
zentiva k.s., Česká republika - goserelín - 44 - cytostatica
reseligo 3,6 mg
zentiva k.s., Česká republika - goserelín - 44 - cytostatica
xtandi
astellas pharma europe b.v. - enzalutamide - prostatické nádory - endokrinná terapia - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
dormicum 7,5 mg
roche slovensko - midazolam - 57 - hypnotica, sedativa
anastrozol-ratiopharm 1 mg
ratiopharm gmbh, nemecko - anastrozol - 44 - cytostatica
egistrozol
egis pharmaceuticals plc, maďarsko - anastrozol - 44 - cytostatica
anastrozole pharmacenter
pharmevid s.r.o., slovensko - anastrozol - 44 - cytostatica
firmagon
ferring pharmaceuticals a/s - degarelix - prostatické nádory - endokrinná terapia - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.